TY - JOUR T1 - Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications JF - medRxiv DO - 10.1101/19006429 SP - 19006429 AU - Daniel Spakowicz AU - Rebecca Hoyd AU - Mitchell Muniak AU - Marium Husain AU - James S. Bassett AU - Lei Wang AU - Gabriel Tinoco AU - Sandip H. Patel AU - Jarred Burkart AU - Abdul Miah AU - Mingjia Li AU - Andrew Johns AU - Madison Grogan AU - David P. Carbone AU - Claire F. Verschraegen AU - Kari L. Kendra AU - Gregory A. Otterson AU - Lang Li AU - Carolyn J. Presley AU - Dwight H. Owen Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/11/14/19006429.abstract N2 - The microbiome has been shown to affect the response to Immune Checkpoint Inhibitors (ICIs) in a small number of cancers. Here, we sought to more broadly survey cancers to identify those in which the microbiome will play a role using retrospective analyses. We created a causal model for the relationship between medications, the microbiome and ICI response and used it to guide the abstraction of electronic health records of 690 patients who received ICI therapy for advanced cancer. Medications associated with changes to the microbiome including antibiotics, corticosteroids, proton pump inhibitors, histamine receptor blockers, non-steroid anti-inflammatories and statins were abstracted. We tested the effect of medication timing on overall survival (OS) and evaluated the robustness of medication effects in each cancer. Finally, we compared the size of the effect observed for antibiotics classes to taxa correlated with ICI response and a literature review of culture-based antibiotic susceptibilities. Of the medications assessed, only antibiotics and corticosteroids significantly associated with lower OS. The hazard ratios (HRs) for antibiotics and corticosteroids were highest near the start of ICI treatment but remained significant when given prior to ICI. Antibiotics and corticosteroids remained significantly associated with OS even when controlling for multiple factors such as Eastern Cooperative Oncology Group performance status, Charlson Comorbidity Index score, and stage. When grouping antibiotics by class, β-lactams showed the strongest association with OS across all tested cancers. The timing and strength of these effects after controlling for confounding factors are consistent with role for the microbiome in response to ICIs.Competing Interest StatementDHO has a consulting or advisory role to L&M Policy Research and AstraZeneca. DHO has research funding from Bristol-Myers Squibb, Palobiofarma, Merch Sharp & Dohme and Genentech/Roche. DHO received travel, accommodations and/or expenses from AstraZeneca. DPC is on the advisory board of Abbvie, AMGEN, Ariad, AZ, Biocept, BI, BMS, Celgene, EMD Serono, Genentech, Gritstone, Helsinn, Inivata, Inovio, Janssen, Loxo Oncology, Merck, MSD, Pfizer, Roche, Takeda, and Trinity. DPC received honoraria from AstraZeneca and Nexus Oncology. DPC is a consultant for Abbvie, Agenus, Ariad, Celgene, Genentech, Incyte, Inivata, Janssen, Kyowa Kirin, Loxo, MSD, Novartis, Pfizer and Takeda.Funding StatementThis project was supported by The Ohio State University Center for Clinical and Translational Science grant support (National Center for Advancing Translational Sciences, Grant 8UL1TR000090-05) and a P30 CCSG award ( 2 P30 CA016058-42). Daniel Spakowicz is supported by a Pelotonia New Investigator Award and Carolyn Presley is a Paul Calabresi Scholar supported by the OSU K12 Training Grant for Clinical Faculty Investigators (5K12 CA133250-09). No funding body was involved in the design of the study or the collection, analysis, or interpretation of data, or in writing the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesScripts to reproduce all figures and analyses can be found at https://github.com/spakowiczlab/co-med-io. https://github.com/spakowiczlab/co-med-io ICIsImmune Checkpoint InhibitorsOSOverall SurvivalABxAntibioticsCSCorticosteroidsCCICharlson Comorbidity IndexPSEastern Cooperative Oncology Group Performance StatusBMIBody Mass IndexNSCLCNon-Small Cell Lung CancerRCCRenal Cell CarcinomaHNSCHead and Neck Squamous Cell Carcinoma ER -